First successful hemoadsorption using CytoSorb ® in a septic pediatric patient in Kazakhstan: A case report

Askhat Saparov, Vitaliy Sazonov, Zaure Tobylbayeva, Samat Isakov, Almat Bekpan, Darkhan Autalipov, Bakhyt Muratbekova, Zhazira Manaybekova, Vitaliy Anikin

2019

Closed access Metadata (CSL-JSON)

DOI 10.1177/0391398818819953

Data confidence 70 medium

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

PURPOSE: For the first time in Kazakhstan, we have used a combined extracorporeal support, by including the CytoSorb system in a continuous veno-venous hemofiltration system in an 8-month-old patient with a body weight of 5600 g. RESULTS: The CytoSorb therapy session resulted in a reduction of inflammation markers IL-6, S100, procalcitonin, and C-reactive protein. Simultaneously, the level of transaminases, creatine kinase, and troponin were normalized, by the end of the session patient hemodynamics were stable and there was no need for vasopressors, acid-base balance was maintained, and the patient was weaned from mechanical ventilation to spontaneous breathing. CONCLUSION: Treatment using the CytoSorb device was safe and well-tolerated in a pediatric patient and has proven its practical value as an adjuvant therapy for sepsis in pediatric patient populations.